By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
We are on a mission to prevent and defeat life-threatening viral diseases by delivering revolutionary, allogeneic cell therapies to patients fighting viral infections.
Restoring Immunity
Our approach aims to restore viral immunity for patients fighting life-threatening infections through allogeneic, off-the-shelf, virus-specific T cell (VST) therapies.
Our Platform
Our proprietary platform develops VST therapy candidates designed to restore immunity in patients with T cell deficiencies.
We are committed to preventing and defeating life-threatening viral diseases by delivering revolutionary, allogeneic cell therapies to patients fighting viral infections.
We are committed to preventing and defeating life-threatening viral diseases with revolutionary, allogeneic cell therapies. With more than 20 years of clinical experience in virus-specific T cell therapies (VSTs), our team is progressing products from early-stage discovery to clinical trials, regulatory approval and commercialization.
Baylor College of Medicine
Our technology platform was developed by world-class scientists at the Baylor College of Medicine’s Center for Cell and Gene Therapy. We continue to collaborate on basic and translational research of novel cell therapies through sponsored research agreements. This collaboration with the Center for Cell and Gene Therapy has enabled us to translate our research into clinical protocols at Texas Children’s Hospital and Houston Methodist Hospital in pediatric and adult patients, respectively.
ElevateBio BaseCamp
An affiliate of ElevateBio, AlloVir has access to the clinical, manufacturing, and commercial expertise of ElevateBio BaseCamp, a centralized cell and gene therapy manufacturing facility and innovation hub.
AlloVir is the global leader in developing VST immunotherapies
We develop highly innovative, allogeneic, off-the-shelf, virus-specific T cell (VST) therapies designed to prevent and treat life-threatening viral diseases.
Our Pipeline
Our allogeneic, off-the-shelf VST therapy candidates target 11 different devastating viruses as treatment or prevention.
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
